Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most grants, cystic fibrosis & pain ISS, general education/advocacy) | February 27, 2026 (Beta thalassemia & sickle cell ISS RFP)
Funding Amounts: No strict cap; requests should be fair market value. Typically, funding will not exceed 30% of an organization's annual operating budget per year; up to 35% overhead allowed for ISS.
Summary: Supports independent medical education, patient advocacy, and scientific initiatives in serious diseases aligned with Vertex’s research focus.
Key Information: Funding is available only for organizations (not individuals) in countries where Vertex operates.